11.23 USD
↘ 0.19 (1.66%)AT CLOSE (11:59 AM EDT)
Immunic, Inc. Common Stock
IMUXNASDAQ • USD
11.41
↗ 0.18 (1.60%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
11.41
↗ 0.18 (1.60%)
Market: CLOSED
IMUX is currently priced at $11.20. The stock presents a bearish profile across the board: technical indicators signal "Sell" and our fundamental models agree with a "Sell" rating. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. On the valuation side, IMUX appears attractively valued relative to sector peers across key multiples.
Technical & fundamental data as of Sep 14, 2026.
Open?$11.43
High?$11.46
Low?$11.04
Prev. Close?$11.42
Volume?253.4K
Avg. Volume?242.5K
VWAP?$11.25
Rel. Volume?1.04x
Bid / Ask
Bid?$9.46 × 100
Ask?$13.48 × 100
Spread?$4.02
Midpoint?$11.47
Valuation & Ratios
Market Cap?155.8M
Shares Out?13.6M
Float?120.7M
Float %?88.6%
P/E Ratio?N/A
P/B Ratio?1.22
EPS?-$8.18
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
Address
1200 AVENUE OF THE AMERICAS
NEW YORK, X1 10036
Phone: (332) 255-9818
NEW YORK, X1 10036
Phone: (332) 255-9818
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?65
Short Sent.?41
Piotroski F-Score?0/9Weak
Altman Z-Score?-4.47Distress
Confidence?49%Low
Short InterestHigh
Short % of Float?1.24%Low
Short Interest?1.5M
Days to Cover?7.7
Free Float120.7M
Avg Daily Volume194.8K
Settlement Date2026-08-31
Financial Health
Current Ratio?5.05Strong
Quick Ratio?5.05Strong
Cash Ratio?4.96Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?1.22CHEAP▾
Peers100
S&P93
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-0.0CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-87.5%WEAK▾
S&P3
ROA?-70.1%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-88049000
Enterprise Value?$721.8K
Fundamentals ratios updated end of day